Study: Ozempic Cuts Heart Disease Risk by 20% Regardless of Weight Loss
The Facts
- A study of over 17,604 people aged 45 and over has found that semaglutide, the active ingredient in Wegovy and Ozempic, reduced the risk of major cardiac events by 20% regardless of whether participants lose weight or the amount of weight they lose during treatment.
- Researchers discovered that people with a BMI of 27 — the average for UK adults, which classifies them as overweight but not obese — experienced similar cardiovascular benefits as those with the highest BMI scores in the severely obese category.
- The study found that shrinking waist circumference accounted for approximately one-third of semaglutide's cardiovascular benefits, while the remaining two-thirds of the heart health improvements remain unexplained by current medical understanding.
The Spin
Narrative A
GLP-1 drugs represent a revolutionary breakthrough that transforms obesity treatment and delivers extraordinary health benefits beyond weight loss. These medications reduce risks of dementia, addiction, heart disease, and dozens of other conditions by 10-20%, offering hope for previously untreatable diseases. The drugs energize medical research and prove obesity is a biological condition requiring chronic treatment.
Narrative B
GLP-1 drugs like Ozempic aren't miracle cures and come with serious risks that outweigh their modest benefits. These medications cause dangerous complications including pancreatitis, kidney problems, and semi-starvation states where patients eat as few as 600 calories daily. Most people regain 60-70% of lost weight after stopping, making them ineffective long-term solutions to obesity and associated conditions.
Metaculus Prediction
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.17.1